Compare CVS Health Corp (CVS) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Invesco Preferred ETF — how do they compare? CVS Health Corp trades at $86.16 (market cap $112.29B), while Invesco Preferred ETF trades at $10.01 (market cap $3.60B). The key difference: CVS Health Corp is far larger — about 31.2× Invesco Preferred ETF's market cap, and CVS Health Corp pays a 3.03% dividend while Invesco Preferred ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Invesco Preferred ETF for 95 Days on average.
| CVS | PGX | |
|---|---|---|
Market Cap | $112.29B | $3.60B |
Volume | 7,763,676 | 5,986,026 |
Sector | Health | — |
52-Week High | $110.60 | $11.61 |
52-Week Low | $70.08 | $9.97 |
Typical Hold Time | 83 Days | 95 Days |
Enterprise Value | $174.64B | — |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $86.16, down 2.04% for the day, amid a bearish technical signal. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.58 exceeding the $1.85 estimate. Revenue grew to $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst consensus is overwhelmingly positive, with 35 of 41 analysts rating the stock a Buy and a consensus price target of $111.20, implying significant upside. Recent news highlights Aetna's 2027 Medicare plan updates and a quarterly dividend declaration.
The outlook for CVS remains favorable based on fundamental strength and analyst optimism, but risks include reimbursement pressure, regulatory scrutiny, and a high debt load. The stock's current valuation metrics, such as a P/E of 23.17 and P/S of 0.27, appear reasonable relative to historical levels, supporting a constructive view for long-term investors despite near-term technical weakness.
PGX trades at $10.01 with a modest 0.4% daily gain, but technical indicators signal a bearish trend with moving averages unanimously negative. The stock shows neutral oscillators with RSI levels suggesting potential oversold conditions. Recent corporate actions include scheduled dividends for July and September 2026 at $0.06 per share. Support and resistance levels cluster tightly around $10, indicating consolidation near current price levels.
Investment outlook remains cautious given the bearish technical picture and lack of current fundamental data. The stock faces headwinds from technical selling pressure while dividend payments provide some income support. Key risks include market volatility and the need for improved fundamental performance to sustain price levels above current support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
